Design Transfer of Combination Products from Development to Production
A medical device company developing combination products
A medical device company with combination products needed to make the design transfer from development to production more efficient while overcoming regulatory hurdles under the EU MDR and the FDA.
The challenge
The situation
Regulatory uncertainties under the EU MDR led to compliance delays, while the complexity of the FDA requirements under 21 CFR Part 4 created additional coordination needs. Limited internal resources and a lack of specialist expertise compounded the situation, and operational gaps in the transition from development to production delayed market entry through lengthy approval processes.
Our approach
What we delivered
Gap analysis to assess the design transfer and the compliance gaps
Regulatory support on the EU MDR and FDA 21 CFR Part 4
Process optimization for the transition from development to production
Cross-functional expertise to close internal resource and knowledge gaps
Implementation of modern processes for a more efficient production workflow
The outcome
Results & impact
25% faster regulatory approval
Regulatory approval was accelerated by 25 percent.
15% reduction in transfer costs
The cost of the design transfer decreased by 15 percent.
Accelerated market entry
Market entry was achieved faster than previously possible.
In summary
The market launch was successful and faster, with reduced costs, a more efficient production process, and greater competitiveness.
Regulations & standards considered
- EU MDR (Regulation (EU) 2017/745)
- FDA 21 CFR Part 4 (combination products)
Similar projects
More on MedTech →Sources
- https://theentourage.de/case-study/design-transfer-kombinationprodukte/ (live case study, accessed 2026-06-14)
Your project
A comparable project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +39 02 8904 1000
info@theentourage.it
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences



